Sihuan Pharmaceutical Holdings Group Ltd (SHPHF) Stock Price, Trades & News

Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	3.95
Equity-to-Asset	0.5
Debt-to-Equity	0.17
Debt-to-EBITDA	1.2
Interest Coverage	1.86
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.64	Distress Grey Safe
Beneish M-Score	-2	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	6.7
	3-Year FCF Growth Rate	26.3
	3-Year Book Growth Rate	8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	102.42
	Future 3-5Y Total Revenue Growth Rate Estimate	23.57

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	9-Day RSI	0.01
	14-Day RSI	0.14
	6-1 Month Momentum %	17.93
	12-1 Month Momentum %	86.45

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.8
	Quick Ratio	1.64
	Cash Ratio	1.08
	Days Inventory	222.94
	Days Sales Outstanding	100.34
	Days Payable	135.3

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.08
	Dividend Payout Ratio	0.5
	3-Year Dividend Growth Rate	-11.7
	Forward Dividend Yield %	2.15
	5-Year Yield-on-Cost %	1.03
	3-Year Average Share Buyback Ratio	1
	Shareholder Yield %	4.7

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	68.84
	Operating Margin %	14.33
	Net Margin %	6.85
	EBITDA Margin %	32.24
	FCF Margin %	-8.25
	OCF Margin %	-0.84
	ROE %	3.72
	ROA %	1.66
	ROIC %	2.48
	3-Year ROIIC %	364.62
	ROC (Joel Greenblatt) %	24.43
	ROCE %	8.35
	Years of Profitability over Past 10-Year	6
	Moat Score	3
	Tariff Resilience Score	5

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	37.73
	Forward PE Ratio	14.41
	PE Ratio without NRI	48.82
	Shiller PE Ratio	50.51
	PS Ratio	2.63
	PB Ratio	1.16
	Price-to-Tangible-Book	1.44
	EV-to-EBIT	7.67
	EV-to-Forward-EBIT	10.59
	EV-to-EBITDA	5.62
	EV-to-Revenue	1.81
	EV-to-Forward-Revenue	2.66
	EV-to-FCF	-21.88
	Price-to-GF-Value	0.72
	Price-to-Projected-FCF	1.62
	Price-to-Median-PS-Value	0.59
	Price-to-Graham-Number	1.62
	Price-to-Net-Current-Asset-Value	6.49
	Earnings Yield (Greenblatt) %	13.04
	FCF Yield %	-3.19
	Forward Rate of Return (Yacktman) %	17.98

GF Value™: $0.18

SHPHF

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with SHPHF. Try a 7-Day Free Trial to check it out.

Sihuan Pharmaceutical Holdings Group Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Sihuan Pharmaceutical Holdings Group Ltd Stock Events

Financials Calendars

Event	Date	Price ($)
Second quarter earnings results for 2026	2026-08-28	In 60 days
HKD 0.010900 Cash Dividend	2026-06-30	In 1 day
General meeting for 2025	2026-06-26 10:30	0.13 (+0.00%)
Annual report for 2025	2026-04-27	0.19 (+0.00%)
HKD 0.010900 Cash Dividend	2025-09-26	0.10 (+0.00%)
Second quarter earnings results for 2025	2025-08-29	0.10 (+0.00%)
General meeting for 2024	2025-06-06 10:30	0.10 (+0.00%)
Annual report for 2024	2025-04-28	0.12 (+0.00%)
HKD 0.021000 Cash Dividend	2024-09-27	0.07 (+0.00%)
Second quarter earnings results for 2024	2024-08-30	0.07 (+0.00%)

Show

Entries

Guru Commentaries on OTCPK:SHPHF

No articles.

Press Release

	Subject	Date
	Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment	2025-05-15
	Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023	2023-10-14
	Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA	2023-06-27
	Sihuan Pharmaceutical(0460.HK): Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing	2023-01-04

10/Page

Articles on Sihuan Pharmaceutical Holdings Group Ltd

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.